文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.

作者信息

Ko Ryo, Kenmotsu Hirotsugu, Serizawa Masakuni, Koh Yasuhiro, Wakuda Kazushige, Ono Akira, Taira Tetsuhiko, Naito Tateaki, Murakami Haruyasu, Isaka Mitsuhiro, Endo Masahiro, Nakajima Takashi, Ohde Yasuhisa, Yamamoto Nobuyuki, Takahashi Kazuhisa, Takahashi Toshiaki

机构信息

Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.

Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

出版信息

BMC Cancer. 2016 Nov 8;16(1):864. doi: 10.1186/s12885-016-2902-0.

DOI:10.1186/s12885-016-2902-0
PMID:27821131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5100094/
Abstract

BACKGROUND: The majority of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation eventually develop resistance to EGFR tyrosine kinase inhibitors (TKIs). Minimal information exists regarding genetic alterations in rebiopsy samples from Asian NSCLC patients who develop acquired resistance to EGFR-TKIs. METHODS: We retrospectively reviewed the medical records of patients with NSCLC harboring EGFR mutations who had undergone rebiopsies after developing acquired resistance to EGFR-TKIs. We analyzed 27 practicable samples using a tumor genotyping panel to assess 23 hot-spot sites of genetic alterations in nine genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN, and HER2), gene copy number of EGFR, MET, PIK3CA, FGFR1, and FGFR2, and ALK, ROS1, and RET fusions. Additionally, 34 samples were analyzed by commercially available EGFR mutation tests. RESULTS: Sixty-one patients underwent rebiopsy. Twenty-seven samples were analyzed using our tumor genotyping panel, and 34 samples were analyzed for EGFR mutations only by commercial clinical laboratories. Twenty-one patients (34 %) had EGFR T790M mutation. Using our tumor genotyping panel, MET gene copy number gain was observed in two of 27 (7 %) samples. Twenty patients received continuous treatment with EGFR-TKIs even after disease progression, and 11 of these patients had T790M mutation in rebiopsy samples. In contrast, only 10 of 41 patients who finished EGFR-TKI treatment at disease progression had T790M mutation. The frequency of T790M mutation in patients who received continuous treatment with EGFR-TKIs after disease progression was significantly higher than that in patients who finished EGFR-TKI treatment at disease progression (55 % versus 24 %, p = 0.018). CONCLUSIONS: The frequency of T790M mutation in this study was lower than that in previous reports examining western patients. These results suggest that continuous treatment with EGFR-TKI after disease progression may enhance the frequency of EGFR T790M mutation in rebiopsy samples.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dfa/5100094/3250f02bbcad/12885_2016_2902_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dfa/5100094/952197d3025c/12885_2016_2902_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dfa/5100094/5aa93c1a5857/12885_2016_2902_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dfa/5100094/3250f02bbcad/12885_2016_2902_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dfa/5100094/952197d3025c/12885_2016_2902_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dfa/5100094/5aa93c1a5857/12885_2016_2902_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dfa/5100094/3250f02bbcad/12885_2016_2902_Fig3_HTML.jpg

相似文献

[1]
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.

BMC Cancer. 2016-11-8

[2]
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

Lung Cancer. 2014-3-23

[3]
Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.

Clin Lung Cancer. 2017-8-10

[4]
Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.

Cancer Sci. 2016-7

[5]
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.

Clin Lung Cancer. 2017-5-10

[6]
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.

Cancer. 2013-9-16

[7]
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.

Lung Cancer. 2013-9-3

[8]
Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.

Lung Cancer. 2017-9-12

[9]
Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.

Mol Oncol. 2019-4-10

[10]
Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.

Lung Cancer. 2016-7-22

引用本文的文献

[1]
Efficacy and safety of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in retreatment of patients without T790M.

Transl Lung Cancer Res. 2025-7-31

[2]
T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma.

Tanaffos. 2022-3

[3]
Changes in HER3 expression profiles between primary and recurrent gynecological cancers.

Cancer Cell Int. 2023-2-3

[4]
Comparison of T790M Acquisition After Treatment With First- and Second-Generation Tyrosine-Kinase Inhibitors: A Systematic Review and Network Meta-Analysis.

Front Oncol. 2022-6-28

[5]
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With Mutation-Positive NSCLC.

Clin Med Insights Oncol. 2022-6-24

[6]
Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review.

Transl Lung Cancer Res. 2022-5

[7]
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.

Medicina (Kaunas). 2021-9-3

[8]
A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor () Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study.

Cancers (Basel). 2021-6-25

[9]
Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Cureus. 2020-12-17

[10]
Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs.

Thorac Cancer. 2021-3

本文引用的文献

[1]
Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.

Target Oncol. 2016-4

[2]
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.

Oncotarget. 2015-9-22

[3]
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

Lancet Oncol. 2015-7-6

[4]
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

Lung Cancer. 2014-3-23

[5]
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.

Br J Cancer. 2014-4-17

[6]
Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.

Cancer. 2014-4-3

[7]
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.

BMC Cancer. 2013-12-27

[8]
Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.

Cancer. 2013-9-16

[9]
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

J Clin Oncol. 2013-7-1

[10]
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Clin Cancer Res. 2013-3-7

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索